Study on Cefiderocol and Klebsiella Bacteria Resistance
Part of Infections clinical trials.
This trial looks at how well the antibiotic cefiderocol works against a type of Klebsiella bacteria that is hard to treat and more likely to cause severe infections. It may help find better treatments for patients with these infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an infection caused by a certain type of Klebsiella bacteria, confirmed by lab tests.
- You are of any age or gender.
- You have not taken antibiotics in the 2 days before your sample was taken.
- Your medical records are complete and your samples are good enough for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibiotic combination (ceftazidime-avibactam) for people with difficult-to-treat Klebsiella pneumoniae infections that are resistant to carbapenem antibiotics due to a specific enzyme. It may help if you have a skin, chest, surgical wound, or urinary tract infection from this resistant bacteria.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This research study examines how certain bacteria become resistant to multiple antibiotics and develop protective biofilms. Researchers will study samples from patients with hospital-acquired infections to better understand why some bacteria survive antibiotics and how to fight them in the future.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial tests whether the antibiotic cefotetan works as well as or better than standard treatments for E. coli bloodstream infections. You may be eligible if you have a confirmed E. coli infection in your blood that started in your urinary or genital area, and you have just started antibiotics in the hospital.
This trial looks at how well certain penicillin-type antibiotics work for treating a bloodstream infection caused by a bacterium called Enterococcus faecalis. It may help doctors know which treatment is best for patients with this infection.
Hear when a new Carbapenem-resistant Hypervirulent Klebsiella Pneumoniae Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.